Vir Biotechnology, Inc. Common Stock
VIRVir Biotechnology, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to treat and prevent infectious diseases. Founded with a mission to enhance immune responses and improve healthcare outcomes, Vir leverages cutting-edge science in immunology and antibody technologies to address global health challenges, including viral infections such as influenza, HIV, and COVID-19.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 3, 2010 | $0.03 | 2010-11-03 | 2010-11-05 |
| September 17, 2010 | $0.03 | 2010-08-25 | 2010-08-27 |
| June 11, 2010 | $0.03 | 2010-05-12 | 2010-05-14 |
| March 19, 2010 | $0.03 | 2010-03-03 | 2010-03-05 |
| December 1, 2009 | $0.03 | 2009-11-06 | 2009-11-10 |
Dividends Summary
- Vir Biotechnology, Inc. Common Stock has issued 13 dividend payments over the past 3 years
- The most recent dividend was paid 5513 days ago, on December 3, 2010
- The highest dividend payed out to investors during this period was $0.03 per share
- The average dividend paid during this period was $0.03 per share.
Company News
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
GSK and Biogen (BIIB) are in the spotlight following litigation updates and drug approval, respectively.
Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullis...
A more selective small-cap index has consistently outperformed the Russell 2000
